BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34381018)

  • 1. Alcohol-abuse drug disulfiram targets pediatric glioma via MLL degradation.
    Meier S; Cantilena S; Niklison Chirou MV; Anderson J; Hargrave D; Salomoni P; de Boer J; Michod D
    Cell Death Dis; 2021 Aug; 12(8):785. PubMed ID: 34381018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing disulfiram, an alcohol-abuse drug, in neuroblastoma causes KAT2A downregulation and in vivo activity with a water/oil emulsion.
    Beaudry A; Jacques-Ricard S; Darracq A; Sgarioto N; Garcia A; García TR; Lemieux W; Béland K; Haddad E; Cordeiro P; Duval M; McGraw S; Richer C; Caron M; Marois F; St-Onge P; Sinnett D; Banquy X; Raynal NJ
    Sci Rep; 2023 Sep; 13(1):16443. PubMed ID: 37777587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4.
    Skrott Z; Mistrik M; Andersen KK; Friis S; Majera D; Gursky J; Ozdian T; Bartkova J; Turi Z; Moudry P; Kraus M; Michalova M; Vaclavkova J; Dzubak P; Vrobel I; Pouckova P; Sedlacek J; Miklovicova A; Kutt A; Li J; Mattova J; Driessen C; Dou QP; Olsen J; Hajduch M; Cvek B; Deshaies RJ; Bartek J
    Nature; 2017 Dec; 552(7684):194-199. PubMed ID: 29211715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA-approved disulfiram as a novel treatment for aggressive leukemia.
    Karsa M; Xiao L; Ronca E; Bongers A; Spurling D; Karsa A; Cantilena S; Mariana A; Failes TW; Arndt GM; Cheung LC; Kotecha RS; Sutton R; Lock RB; Williams O; de Boer J; Haber M; Norris MD; Henderson MJ; Somers K
    J Mol Med (Berl); 2024 Apr; 102(4):507-519. PubMed ID: 38349407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
    Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
    Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.
    Zhang X; Zheng X; Yang H; Yan J; Fu X; Wei R; Xu X; Zhang Z; Yu A; Zhou K; Ding J; Geng M; Huang X
    Cancer Lett; 2018 Sep; 431():150-160. PubMed ID: 29857126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in chromatin machinery and pediatric high-grade glioma.
    Lulla RR; Saratsis AM; Hashizume R
    Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
    Bernt KM; Zhu N; Sinha AU; Vempati S; Faber J; Krivtsov AV; Feng Z; Punt N; Daigle A; Bullinger L; Pollock RM; Richon VM; Kung AL; Armstrong SA
    Cancer Cell; 2011 Jul; 20(1):66-78. PubMed ID: 21741597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone H3K9 methyltransferase SETDB1 overexpression correlates with pediatric high-grade gliomas progression and prognosis.
    Klonou A; Korkolopoulou P; Giannopoulou AI; Kanakoglou DS; Pampalou A; Gargalionis AN; Sarantis P; Mitsios A; Sgouros S; Papavassiliou AG; Piperi C
    J Mol Med (Berl); 2023 Apr; 101(4):387-401. PubMed ID: 36811655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.
    Fontebasso AM; Schwartzentruber J; Khuong-Quang DA; Liu XY; Sturm D; Korshunov A; Jones DT; Witt H; Kool M; Albrecht S; Fleming A; Hadjadj D; Busche S; Lepage P; Montpetit A; Staffa A; Gerges N; Zakrzewska M; Zakrzewski K; Liberski PP; Hauser P; Garami M; Klekner A; Bognar L; Zadeh G; Faury D; Pfister SM; Jabado N; Majewski J
    Acta Neuropathol; 2013 May; 125(5):659-69. PubMed ID: 23417712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pygo2 functions as a prognostic factor for glioma due to its up-regulation of H3K4me3 and promotion of MLL1/MLL2 complex recruitment.
    Zhou C; Zhang Y; Dai J; Zhou M; Liu M; Wang Y; Chen XZ; Tang J
    Sci Rep; 2016 Feb; 6():22066. PubMed ID: 26902498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance.
    Huo H; Magro PG; Pietsch EC; Patel BB; Scotto KW
    Cancer Res; 2010 Nov; 70(21):8726-35. PubMed ID: 20861184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
    Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
    Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma.
    Chu SH; Feng DF; Ma YB; Zhang H; Zhu ZA; Li ZQ; Jiang PC
    J Transl Med; 2011 Sep; 9():156. PubMed ID: 21936894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
    Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
    Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications.
    Milne TA; Martin ME; Brock HW; Slany RK; Hess JL
    Cancer Res; 2005 Dec; 65(24):11367-74. PubMed ID: 16357144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the Lysosome-Associated Membrane Protein LAMP5 by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation in Leukemia.
    Wang WT; Han C; Sun YM; Chen ZH; Fang K; Huang W; Sun LY; Zeng ZC; Luo XQ; Chen YQ
    Clin Cancer Res; 2019 May; 25(9):2795-2808. PubMed ID: 30651276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of DNA demethylase and histone methyltransferase upregulates Nrf2 in 5-fluorouracil-resistant colon cancer cells.
    Kang KA; Piao MJ; Ryu YS; Kang HK; Chang WY; Keum YS; Hyun JW
    Oncotarget; 2016 Jun; 7(26):40594-40620. PubMed ID: 27259240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.